CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Shah, Nirali N., Highfill, Steven L., Shalabi, Haneen, Yates, Bonnie, Jin, Jianjian, Wolters, Pamela L., Ombrello, Amanda, Steinberg, Seth M., Martin, Staci, Delbrook, Cindy, Hoffman, Leah, Little, Lauren, Ponduri, Anusha, Qin, Haiying, Qureshi, Haris, Dulau-Florea, Alina, Salem, Dalia, Wang, Hao-Wei, Yuan, Constance, Stetler-Stevenson, Maryalice, Panch, Sandhya, Tran, Minh, Mackall, Crystal L., Stroncek, David F., Fry, Terry J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2020
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280047/
https://ncbi.nlm.nih.gov/pubmed/32286905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03279
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια